Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STK17B | O94768 | 1/20 | 0.50 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | LATS1 | O95835 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | P2RY12 | Q9H244 | 9/20 | 0.40 |
| ▸ | BRD4 | O60885 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8184539 | 0.87 | ADORA3 (0.44) | STK17BSTK17AADORA3ADORA2ALATS1 | |
| SCHEMBL3826302 | 0.86 | STK17B (0.54) | STK17BSTK17AADORA3ADORA2ALATS1 | |
| SCHEMBL13428487 | 0.82 | STK17B (0.54) | STK17BSTK17AL3MBTL1LATS1KDM4E | |
| SCHEMBL13428547 | 0.81 | STK17B (0.47) | STK17BSTK17AADORA3ADORA2AL3MBTL1 | |
| SCHEMBL13428494 | 0.80 | STK17B (0.54) | STK17BSTK17AL3MBTL1LATS1MAPT | |
| SCHEMBL3222737 | 0.79 | ALDH1A1 (0.52) | L3MBTL1MAPTP2RY12ALDH1A1 | |
| SCHEMBL3227719 | 0.78 | L3MBTL1 (0.47) | L3MBTL1P2RY12 | |
| SCHEMBL13428798 | 0.78 | KDM4E (0.51) | L3MBTL1KDM4EP2RY12 | |
| SCHEMBL13428793 | 0.77 | L3MBTL1 (0.44) | L3MBTL1P2RY12ALDH1A1 | |
| SCHEMBL5610352 | 0.77 | IDO1 (0.45) | STK17BSTK17AKDM4EMAPTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100069388-A1 | N-HYDROXYACRYLAMIDE COMPOUNDS | ASTELLAS PHARMA INC. (JP) | 2010-03-18 | — | — | US | disclosed |
| US-20100069388-A1 | N-HYDROXYACRYLAMIDE COMPOUNDS | ASTELLAS PHARMA INC. (JP) | 2010-03-18 | — | — | US | disclosed |
| US-20100069388-A1 | N-HYDROXYACRYLAMIDE COMPOUNDS | ASTELLAS PHARMA INC. (JP) | 2010-03-18 | — | — | US | disclosed |
| EP-2099756-A1 | N-HYDROXYACRYLAMIDE COMPOUNDS | Astellas Pharma Inc. (JP) | 2009-09-16 | — | — | EP | disclosed |
| WO-2008075757-A1 | N-HYDROXYACRYLAMIDE COMPOUNDS | ASTELLAS PHARMA INC. (JP) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069388-A1 | N-HYDROXYACRYLAMIDE COMPOUNDS | HDAC1, HDAC11, HDAC2 | STK17B 2348/4885STK17A 1986/4885ADORA3 2507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.